Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

8/28/24 4:01:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KNSA alert in real time by email

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST^®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor Contact

Jonathan Kirshenbaum

(781) 829-3949

[email protected]

Kiniksa Media Contact

Tyler Gagnon

(781) 431-9100

[email protected]

Get the next $KNSA alert in real time by email

Date	Price Target	Rating	Analyst
9/13/2024	$40.00	Buy	Jefferies
5/3/2024	$34.00	Overweight	Wells Fargo
12/29/2021	$37.00 → $34.00	Buy	B of A Securities

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$KNSA

$KNSA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF OPERATING OFFICER Tessari Eben exercised 10,000 units of Class A Ordinary Share at a strike of $1.59 and sold $357,680 worth of Class A Ordinary Share (17,000 units at $21.04), decreasing direct ownership by 6% to 102,975 units (SEC Form 4)

Director Levy Richard S converted options into 1,303 units of Class A Ordinary Share, increasing direct ownership by 10% to 14,200 units (SEC Form 4)

CHAIRMAN & CEO Patel Sanj K exercised 89,561 units of Class A Ordinary Share at a strike of $1.59 and sold $2,059,903 worth of Class A Ordinary Share (89,561 units at $23.00) (SEC Form 4)

$KNSA
Market Insights

Live Market Insights

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

$KNSA
SEC Filings

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$KNSA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$KNSA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$KNSA
Financials

Live finance-specific insights

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

B of A Securities reiterated coverage on Kiniksa Pharmaceuticals with a new price target

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

$KNSA
Press Releases

Fastest customizable press release news feed in the world

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $KNSA

$KNSA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF OPERATING OFFICER Tessari Eben exercised 10,000 units of Class A Ordinary Share at a strike of $1.59 and sold $357,680 worth of Class A Ordinary Share (17,000 units at $21.04), decreasing direct ownership by 6% to 102,975 units (SEC Form 4)

Director Levy Richard S converted options into 1,303 units of Class A Ordinary Share, increasing direct ownership by 10% to 14,200 units (SEC Form 4)

CHAIRMAN & CEO Patel Sanj K exercised 89,561 units of Class A Ordinary Share at a strike of $1.59 and sold $2,059,903 worth of Class A Ordinary Share (89,561 units at $23.00) (SEC Form 4)

$KNSA Market Insights

Live Market Insights

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

$KNSA SEC Filings

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$KNSA Large Ownership Changes

This live feed shows all institutional transactions in real time.

$KNSA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$KNSA Financials

Live finance-specific insights

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

B of A Securities reiterated coverage on Kiniksa Pharmaceuticals with a new price target

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

$KNSA Press Releases

Fastest customizable press release news feed in the world

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

Recent Analyst Ratings for
$KNSA

$KNSA
Insider Trading

$KNSA
Market Insights

$KNSA
SEC Filings

$KNSA
Large Ownership Changes

$KNSA
Analyst Ratings

$KNSA
Financials

$KNSA
Press Releases